1 Al-Aly, Z., Xie, Y. & Bowe, B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 594, 259-264, doi:10.1038/s41586-021-03553-9 (2021).
2 Juthani, P. V. et al. Hospitalisation among vaccine breakthrough COVID-19 infections. Lancet Infect Dis, doi:10.1016/S1473-3099(21)00558-2 (2021).
3 Nixon, D. F. & Ndhlovu, L. C. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. The New England journal of medicine 385, e7, doi:10.1056/NEJMc2107808 (2021).
4 Rana, K., Mohindra, R. & Pinnaka, L. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. The New England journal of medicine 385, e7, doi:10.1056/NEJMc2107808 (2021).
5 Alwan, N. A. The road to addressing Long Covid. Science 373, 491-493, doi:10.1126/science.abg7113 (2021).
6 Xie, Y., Bowe, B. & Al-Aly, Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nature Communications (2021).
7 Bowe, B., Xie, Y., Xu, E. & Al-Aly, Z. Kidney Outcomes in Long COVID. Journal of the American Society of Nephrology, ASN.2021060734, doi:10.1681/asn.2021060734 (2021).
8 Kind, A. J. H. & Buckingham, W. R. Making Neighborhood-Disadvantage Metrics Accessible - The Neighborhood Atlas. The New England journal of medicine 378, 2456-2458, doi:10.1056/NEJMp1802313 (2018).
9 Daugherty, S. E. et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. Bmj 373, n1098, doi:10.1136/bmj.n1098 (2021).
10 Taquet, M. et al. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS medicine 18, e1003773, doi:10.1371/journal.pmed.1003773 (2021).
11 Davis, H. E. et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 38, 101019, doi:10.1016/j.eclinm.2021.101019 (2021).
12 Taquet, M., Geddes, J. R., Husain, M., Luciano, S. & Harrison, P. J. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry 8, 416-427, doi:10.1016/S2215-0366(21)00084-5 (2021).
13 Ayoubkhani, D. et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. Bmj 372, n693, doi:10.1136/bmj.n693 (2021).
14 Xie, Y. et al. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. Bmj 365, l1580, doi:10.1136/bmj.l1580 (2019).
15 Xie, Y., Bowe, B., Maddukuri, G. & Al-Aly, Z. Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza: cohort study. Bmj, doi:http://dx.doi.org/10.1136/bmj.m4677 (2021).
16 Xie, Y. et al. Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes. JAMA internal medicine, doi:10.1001/jamainternmed.2021.2488 (2021).
17 Cai, M. et al. Temporal Trends in Incidence Rates of Lower Extremity Amputation and Associated Risk Factors Among Patients Using Veterans Health Administration Services From 2008 to 2018. JAMA Netw Open 4, e2033953, doi:10.1001/jamanetworkopen.2020.33953 (2021).
18 Cai, M., Bowe, B., Xie, Y. & Al-Aly, Z. Temporal trends of COVID-19 mortality and hospitalisation rates: an observational cohort study from the US Department of Veterans Affairs. BMJ Open 11, e047369, doi:10.1136/bmjopen-2020-047369 (2021).
19 Bowe, B., Xie, Y., Yan, Y. & Al-Aly, Z. Burden of Cause-Specific Mortality Associated With PM2.5 Air Pollution in the United States. JAMA Netw Open 2, e1915834, doi:10.1001/jamanetworkopen.2019.15834 (2019).
20 Bowe, B. et al. Acute Kidney Injury in a National Cohort of Hospitalized US Veterans with COVID-19. Clinical journal of the American Society of Nephrology : CJASN, doi:10.2215/CJN.09610620 (2020).
21 Schneeweiss, S. et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20, 512-522, doi:10.1097/EDE.0b013e3181a663cc (2009).
22 Wei, Y. et al. Short term exposure to fine particulate matter and hospital admission risks and costs in the Medicare population: time stratified, case crossover study. Bmj 367, l6258, doi:10.1136/bmj.l6258 (2019).
23 Aubert, C. E. et al. Best Definitions of Multimorbidity to Identify Patients With High Health Care Resource Utilization. Mayo Clin Proc Innov Qual Outcomes 4, 40-49, doi:10.1016/j.mayocpiqo.2019.09.002 (2020).
24 HCUP CCSR. Healthcare cost and utilization project (HCUP). Agency for Healthcare Research and Quality, Rockville, MD.
25 Olvey, E. L., Clauschee, S. & Malone, D. C. Comparison of critical drug-drug interaction listings: the Department of Veterans Affairs medical system and standard reference compendia. Clin Pharmacol Ther 87, 48-51, doi:10.1038/clpt.2009.198 (2010).
26 Greene, M., Steinman, M. A., McNicholl, I. R. & Valcour, V. Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. Journal of the American Geriatrics Society 62, 447-453, doi:10.1111/jgs.12695 (2014).
27 Rubin, D. B. Causal Inference Through Potential Outcomes and Principal Stratification: Application to Studies with “Censoring” Due to Death. Statistical Science 21, 299-309, 211 (2006).
28 Li, F., Thomas, L. E. & Li, F. Addressing Extreme Propensity Scores via the Overlap Weights. American journal of epidemiology 188, 250-257, doi:10.1093/aje/kwy201 (2019).
29 Thomas, L. E., Li, F. & Pencina, M. J. Overlap Weighting: A Propensity Score Method That Mimics Attributes of a Randomized Clinical Trial. Jama 323, 2417-2418, doi:10.1001/jama.2020.7819 (2020).
30 Lipsitch, M., Tchetgen Tchetgen, E. & Cohen, T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology 21, 383-388, doi:10.1097/EDE.0b013e3181d61eeb (2010).
31 Shi, X., Miao, W. & Tchetgen, E. T. A Selective Review of Negative Control Methods in Epidemiology. Current epidemiology reports 7, 190-202, doi:10.1007/s40471-020-00243-4 (2020).